Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...

India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of women in the U.S.

Rhythm Pharmaceuticals' lone approved product currently generates minimal sales. If you're interested in capitalizing on the ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Eli Lilly and Novo Nordisk are currently the only drugmakers with FDA approved weight-loss medicines on the U.S. market.

Semaglutide has surged in popularity over the past two years, thanks to its remarkable effectiveness as a long-acting GLP-1 ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging ...

Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...

Loss per share was $(0.58), falling short of analyst expectations by $(0.13), or 29.1% (GAAP, Q2 2025). - Research and development expenses rose to $60.2 million in Q2 2025, up from $23.8 million in ...